FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
The U.S. Food and Drug Administration (FDA) has licensed Sanofi’ SA’s four-valent MenQuadfi meningococcal vaccine for use in infants aged six weeks to 23 months old to prevent invasive meningococcal disease. Previously approved for children aged two and older, MenQuadfi is now the first meningococcal vaccine included on the U.S. Centers for Disease Control and […]
Government Cancels $700 Million in Funding for Moderna’s Bird Flu Biologic
The U.S. government has cancelled a contract worth over $700 million awarded to Moderna, Inc. for late-stage development of an mRNA bird flu biologic for humans, as well as the right to purchase the shots. Earlier this year, the Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA) issued the […]
FDA Licenses Moderna’s mNEXSPIKE COVID Shot for Individuals at High Risk for Severe COVID Disease
On May 30, 2025, the U.S. Food and Drug Administration (FDA) licensed mNEXSPIKE (mRNA-1283), a newly developed mRNA COVID-19 biologic for individuals who have previously received any COVID shots and are either 65 years of age or older, or between 12 and 64 years old with at least one underlying medical condition that increases their […]
Moderna Withdraws Application for Combination COVID and Flu Vaccine
Moderna, Inc. withdrew its application for United States licensure for its combination COVID-19/Influenza vaccine known as mRNA-1083. The company stated the decision came “in consultation with” the U.S. Food and Drug Administration (FDA).1 The decision came just one day after the FDA announced the agency would require new clinical trials for approval of annual COVID […]
Meningitis B Vaccine to Be Used for Gonorrhea in England
In August 2025, England will become the first country to offer a vaccine for gonorrhea after cases exceed 85,000 in 2023—the highest gonorrhea levels since recordkeeping began in 1918. The program, offered through the United Kingdom’s National Health Service (NHS), will repurpose the meningitis B vaccine, routinely given to infants, in an attempt to reduce […]
FDA Approves Novavax’s COVID-19 Vaccine With Restrictions
On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved licensure of Novavax, Inc.’s Nuvaxovid protein-based COVID-19 vaccine, which has been available in the United States under Emergency Use Authorization (EUA) since July 2022.1 The decision for a full licensure was postponed while the new agency leadership under the current administration conducted a […]